{"title":"Interleukin-6: possible implications in human diseases.","authors":"T Hirano, T Kishimoto","doi":"10.1007/BF02871787","DOIUrl":null,"url":null,"abstract":"<p><p>It has been demonstrated that interleukin-6 (IL-6) is a cytokine regulating immune response, acute-phase reaction and hematopoiesis. The deregulated expression of IL-6 was suggested to be actually involved in the pathogenesis of polyclonal B cell activation and autoimmune diseases such as rheumatoid arthritis. It could be hypothesized that continuous polyclonal B cell activation may be eventually leading to the generation of plasmacytoma/myeloma, possibly with additional expression of oncogene(s) such as c-myc gene. Therefore, future studies on the gene regulation of IL-6 would provide critical informations on the molecular pathogenesis of these diseases. Furthermore, IL-6 could be used as anti-cancer drug in certain tumors. Moreover, inhibitors of IL-6 such as anti-IL-6 monoclonal antibodies or soluble forms of IL-6 receptors could be useful in the treatment of such polyclonal/monoclonal B cell abnormalities.</p>","PeriodicalId":76092,"journal":{"name":"La Ricerca in clinica e in laboratorio","volume":"19 1","pages":"1-10"},"PeriodicalIF":0.0000,"publicationDate":"1989-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF02871787","citationCount":"29","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"La Ricerca in clinica e in laboratorio","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/BF02871787","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 29
Abstract
It has been demonstrated that interleukin-6 (IL-6) is a cytokine regulating immune response, acute-phase reaction and hematopoiesis. The deregulated expression of IL-6 was suggested to be actually involved in the pathogenesis of polyclonal B cell activation and autoimmune diseases such as rheumatoid arthritis. It could be hypothesized that continuous polyclonal B cell activation may be eventually leading to the generation of plasmacytoma/myeloma, possibly with additional expression of oncogene(s) such as c-myc gene. Therefore, future studies on the gene regulation of IL-6 would provide critical informations on the molecular pathogenesis of these diseases. Furthermore, IL-6 could be used as anti-cancer drug in certain tumors. Moreover, inhibitors of IL-6 such as anti-IL-6 monoclonal antibodies or soluble forms of IL-6 receptors could be useful in the treatment of such polyclonal/monoclonal B cell abnormalities.